Liver Fibrogenesis in Non-Alcoholic Steatohepatitis

Bian, Zhaolian; Ma, Xiong

doi:10.3389/fphys.2012.00248

Cited by 32 publications

(29 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 The relationship of adipokines with NAFLD has been extensively investigated in several previous studies, 32,33 but the published reports have yielded conflicting results regarding the role of adipokines in the pathogenesis of NAFLD. 34,35 In the present study, we found a significant association of IL-6 with lobular inflammation and fibrosis in NAFLD. So, our results are in line with current scientific knowledge regarding this issue.…”

Section: Ercin Et Almentioning

confidence: 74%

Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease

Erçin

Doğru

Genç

et al. 2015

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

show abstract

Section: Ercin Et Almentioning

confidence: 74%

Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease

Erçin

Doğru

Genç

et al. 2015

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

show abstract

“…In one model, Otsuka Long-Evans Tokishima Fatty (OLETF) rats were fed with a methionine-and choline-deficient (MCD) diet [56,94]. In this model a diet mixed with silymarin 0.5 % w/w (approx.…”

Section: Animal Modelsmentioning

confidence: 99%

The potential of silymarin for the treatment of hepatic disorders

et al. 2016

View full text Add to dashboard Cite

Silymarin has long been used as a hepatoprotective remedy. Chronic toxicity studies in rodents have confirmed that silymarin has a very low toxicity. These data support its history as a safe medication in hepatic diseases. In the last years, several studies expanded our understanding of the pharmacology of silymarin and its molecular mechanisms of action. These new insights may affect the handling of silymarin in clinical studies and daily practice. Additionally, scientific knowledge in hepatology is constantly evolving with, particularly, an increase in the field of non-alcoholic fatty liver disease which is considered today as the most frequent liver disease worldwide. In this review, we will describe scientific evidence for the effectiveness of silymarin in hepatic disorders. We will focus on silymarin's pharmacological effects in non-alcoholic fatty liver disease and on its well described effects in alcoholic liver disease and acute intoxications, e.g. with Amanita species. We will discuss the relevance of pharmacological data as a function of doses or concentrations required for a given effect and of concentrations achieved in the target tissues. Many pharmacological effects of silymarin can be attributed to effects downstream or upstream of its antioxidative and membrane-stabilizing properties. However, despite promising new experimental and clinical data further clinical studies are required including long-term observations and the application of hard clinical endpoints such as survival rates, to further support silymarin's use for the treatment of hepatic diseases.

show abstract

“…IL-6 activates signal transducer and activator of transcription 3, which induces cell proliferation and antiapoptotic mechanisms. TNF-α activates pro-oncogenic pathways, including c-Jun N-terminal kinase, nuclear factor kappa-light-chain-enhancer of activated B cells, mammalian target of rapamycin, and the extracellular signal-regulated kinases 29–32. interestingly, several studies indicated that both dietary and genetic obesity could promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF-α expression 33–36…”

Section: Introductionmentioning

confidence: 99%

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Ali

Laçin

Abdel-Wahab³

et al. 2017

OTT

View full text Add to dashboard Cite

The epidemic of insulin resistance, obesity, and metabolic syndrome has led to the emergence of nonalcoholic steatohepatitis (NASH) as the most common cause of liver disease in the US. Patients with NASH are at an increased risk for hepatic disease-related morbidity and death, and chronic inflammation in NASH patients can lead to hepatocellular carcinoma (HCC). The prevalence of HCC is higher in males than in females, and genetic studies have identified androgen and androgen receptors (ARs) as partially responsible for the gender disparity in the development of liver disease and HCC. Although many factors are known to play important roles in the progression of inflammation in NASH patients, the role of androgen and AR in the progression of NASH to HCC has been understudied. This review summarizes the evidence for a potential role of androgen and the AR pathway in the development of NASH-related HCC and in the treatment of HCC. It has been proposed that AR plays a role in the progression of HCC: inhibitory roles in early stages of hepatocarcinogenesis and tumor-promoting roles in advanced stages. AR can be activated by several pathways, even in the absence of androgen. While AR has been explored as a potential therapeutic target in HCC, several clinical trials have failed to demonstrate a clinical benefit of antiandrogen drugs in HCC. This review discusses the potential reason for these observations and discuss the potential future trials design in this important setting.

show abstract

Liver Fibrogenesis in Non-Alcoholic Steatohepatitis

Cited by 32 publications

References 108 publications

Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease

Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease

The potential of silymarin for the treatment of hepatic disorders

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Contact Info

Product

Resources

About